Q-omics provides the consensus-scored RSPH10B profile across patient tissues and cancer cell-line models. RSPH10B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, RSPH10B is differentially expressed in 10, with the highest sampling consensus in KIRP. Additionally, RSPH10B RNA expression shows 14,521 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight READ, KIRP, and TGCT as cancer lineages where RSPH10B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RSPH10B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RSPH10B survival associations across molecular data types. RSPH10B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RSPH10B RNA expression–survival associations across cancer types. High RSPH10B expression shows unfavorable associations in LIHC, ACC, LGG, CESC and KIRC, but favorable associations in READ. The READ Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify READ as the clearest survival context for RSPH10B RNA expression.
This table summarizes RSPH10B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for RSPH10B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RSPH10B shows lower tumor expression in LUSC, LUAD and THCA and higher tumor expression in KIRP, BLCA and STAD. The KIRP box plot shows higher RSPH10B RNA expression in tumor versus normal tissue (log2 FC = +0.058, t-test p < 0.001).
This table shows molecular features associated with RSPH10B in patient tissues and cancer cell lines. In patient samples, RSPH10B shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, RSPH10B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
